The rate of BRCA1 and BRCA2 mutation testing among young women with breast cancer is on the rise, according to a JAMA Oncology study.
The ob-gyn groups issued a statement warning that insurers' prior authorization requirements will hinder patients' access to much needed care.
Counsyl offered its hereditary cancer panel for free to San Francisco women and found that about half who had positive results would not have been screened.
The agency and sponsors detailed how the ovarian cancer drug Lynparza and BRACAnalysis CDx achieved simultaneous FDA review and approval last year.
The Australian High Court rules that isolated genetic material cannot be patented.
The court held that an isolated nucleic acid sequence is not a manner of manufacture and cannot form the basis of a valid patent.
The findings suggested many women don't get the reccomended pre-test counselling. However, with changes in the field, some question whether those current reccomendations will remain appropriate for long.
Color Genomics hopes its recently launched benefits program will enable a broader population to have access to breast and ovarian cancer risk testing.
Quest offers its BRCAvantage test on the MiSeq, has other oncology and neurology NGS tests in development, and is converting all its Sanger tests to NGS.
The saliva-based test identifies mutations in the BRCA1 and BRCA2 genes with 99.99 percent accuracy.
Newsweek discusses the privacy issues raised by digital medicine.
A group of statisticians wants to eliminate researchers' reliance on 'statistical significance,' according to NPR.
In Nature this week: genetic analysis of Anatolian farmers, cotton genome analysis, and more.
Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.